160 related articles for article (PubMed ID: 16937283)
21. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
22. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome.
Camp RL; Rimm EB; Rimm DL
Cancer; 2000 Jan; 88(1):108-13. PubMed ID: 10618612
[TBL] [Abstract][Full Text] [Related]
23. Rate of metastasis in examined lymph nodes as a predictor of extracapsular extension in patients with axillary node-positive breast cancer.
Unal D; Oguz A; Tasdemir A
J Nippon Med Sch; 2014; 81(6):372-7. PubMed ID: 25744480
[TBL] [Abstract][Full Text] [Related]
24. Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes.
Liang F; Qu H; Lin Q; Yang Y; Ruan X; Zhang B; Liu Y; Yu C; Zhang H; Fang X; Hao X
World J Surg Oncol; 2015 Aug; 13():258. PubMed ID: 26311227
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
26. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
Falck AK; Fernö M; Bendahl PO; Rydén L
World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
[TBL] [Abstract][Full Text] [Related]
27. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
28. T-cadherin association with clinicopathological features and prognosis in axillary lymph node-positive breast cancer.
Kong DD; Yang J; Li L; Wang W; Chen YN; Wang SB; Zhou YZ
Breast Cancer Res Treat; 2015 Feb; 150(1):119-26. PubMed ID: 25677746
[TBL] [Abstract][Full Text] [Related]
29. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
30. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
31. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
[TBL] [Abstract][Full Text] [Related]
32. Relationship between the expression of phosphorylated heat shock protein beta-1 with lymph node metastases of breast cancer.
Kaigorodova EV; Zavyalova MV; Bogatyuk MV; Tarabanovskaya NA; Slonimskaya EM; Perelmuter VM
Cancer Biomark; 2015; 15(2):143-50. PubMed ID: 25519015
[TBL] [Abstract][Full Text] [Related]
33. Gene expression signature and the prediction of lymph node metastasis in colorectal cancer by DNA microarray.
Watanabe T; Kobunai T; Tanaka T; Ishihara S; Matsuda K; Nagawa H
Dis Colon Rectum; 2009 Dec; 52(12):1941-8. PubMed ID: 19934913
[TBL] [Abstract][Full Text] [Related]
34. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of nodal ratio on breast cancer recurrence and its potential for incorporation in a new prognostic index.
Martin FT; O'Fearraigh C; Hanley C; Curran C; Sweeney KJ; Kerin MJ
Breast J; 2013; 19(4):388-93. PubMed ID: 23721403
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
37. Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs.
Smeets A; Daemen A; Vanden Bempt I; Gevaert O; Claes B; Wildiers H; Drijkoningen R; Van Hummelen P; Lambrechts D; De Moor B; Neven P; Sotiriou C; Vandorpe T; Paridaens R; Christiaens MR
Breast Cancer Res Treat; 2011 Oct; 129(3):767-76. PubMed ID: 21116709
[TBL] [Abstract][Full Text] [Related]
38. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
39. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.
Spizzo G; Went P; Dirnhofer S; Obrist P; Simon R; Spichtin H; Maurer R; Metzger U; von Castelberg B; Bart R; Stopatschinskaya S; Köchli OR; Haas P; Mross F; Zuber M; Dietrich H; Bischoff S; Mirlacher M; Sauter G; Gastl G
Breast Cancer Res Treat; 2004 Aug; 86(3):207-13. PubMed ID: 15567937
[TBL] [Abstract][Full Text] [Related]
40. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
